AlphAIAlphAI — Financial news for AI agents
minichart.com.sg$MCK

McKesson Q2 Revenue Rises to $110.96B, EPS $10.44; $221M Restructuring Charge

McKesson reported fiscal Q2 2027 revenue of $110.96B, up from $103.15B a year earlier, with net income of $1.22B and EPS of $10.44. The company recorded $221M in restructuring charges for the six-month period. Gross profit rose to $3.96B, while operating income increased to $1.60B. Share buybacks reduced the weighted-average diluted shares, supporting per-share results. The company faces risks related to opiate litigation and rising interest expenses.

Original reporting
minichart.com.sg
Published Nov 5, 2026, 1:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 2:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
McKesson Q2 Revenue Rises to $110.96B, EPS $10.44; $221M Restructuring Charge — source image
Source · minichart.com.sg
Decision brief

The 30-second read

$MCKBullishMed
01

Why it matters

The earnings beat and ongoing share repurchases provide a bullish catalyst, though rising litigation costs and restructuring expenses present risk.

02

Market read

Strong earnings and buybacks may drive short-term upside in MCK and related distribution stocks.

03

What to watch

Litigation exposure from opioid lawsuits may weigh on future earnings.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

McKesson is a leading U.S. drug distributor reporting its Q2 2027 results.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

Q2 2027 revenue rose to $110.96B, EPS $10.44, and $221M restructuring charge disclosed in the filing dated Nov 4, 2026.

Expected impact

likely upward pressure as market prices in earnings beat and buyback support

Evidence & confidence

Revenue and EPS both exceeded prior year, and buybacks reduced share count, indicating strong fundamentals.

Market effects

Sector

Healthcare distribution sector may see broader confidence from McKesson's strong results.

Regional

U.S. market may see modest gains in pharma distribution stocks.

Global

Limited to U.S. healthcare supply chain investors.

Counterpoint

What could challenge this read

Higher restructuring charges could signal underlying cost pressures.

Key entities

  • Company
    McKesson Corp

    U.S. drug distributor reporting Q2 2027 earnings.

Read at source← All news

StoryMcKesson posts strong Q2 FY2027 results, raises FY2027 EPS guidance and completes Precision Medicine Group acquisition

Also covered by

5 outlets

Related articles

$MCKHighAI 8/10

McKesson (MCK) Q2 2027 Earnings Call Transcript

McKesson (MCK) reported Q2 2027 earnings, highlighting investments in employee programs and strategic acquisitions. The company acquired Precision Medicine Group to advance its oncology and biopharma services, and plans to invest in Option Care Health. McKesson also extended its distribution agreement with CVS Health. The company reported strong market trends and growth across its platforms, with a focus on technology and automation to enhance services.

finance.yahoo.com
$MCKHighAI 9/10

Key facts: FY27 Outlook Raised; Deals Expanded; PMG Buy, Segment Split

McKesson (MCK) reported Q2 revenue of $110.96B (+8% YoY) and adjusted EPS of $11.68, beating estimates. It raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. The company extended a drug distribution deal with CVS Health and plans to buy 49% of Option Care Health for $1.4B. McKesson also completed its acquisition of Precision Medicine Group and announced plans to separate its medical-surgical solutions segment.

tradingview.com
$MCKHighAI 9/10

McKesson Corp (MCK) (Q2 2027) Earnings Call Highlights: Raised Guidance, GLP-1 Momentum

McKesson Corp (MCK) raised fiscal 2027 adjusted EPS guidance to $45.60-$46.40, citing 8% revenue growth to $111 billion in Q2. The company acquired Precision Medicine Group for $2.25 billion, extending oncology capabilities. Challenges include lower branded pharmaceutical pricing and medical-surgical segment profit decline. Management discussed strategic investments and long-term growth targets.

finance.yahoo.com
$MCKHighAI 8/10

[McKesson Q2 2027 Earnings Call] McKesson Raises FY2027 EPS Guidance to $45.60-$46.40, Beats on 8% Revenue Growth and 26% GLP-1 Surge

McKesson (MCK) raised its FY2027 EPS guidance to $45.60-$46.40, up from $44.20-$45.00, citing 8% revenue growth and a 26% surge in GLP-1 medication sales. Q2 revenue was $111.0B, up 8%, with adjusted EPS at $11.68, up 18%. The company completed a $2.25B acquisition and plans a $1.4B investment. Management expects 6-10% revenue growth and 12-16% operating profit growth for FY2027.

finance.biggo.com